Target Validation Information
TTD ID T20251
Target Name Voltage-gated potassium channel Kv11.1 (KCNH2)
Type of Target
Successful
Drug Potency against Target Amiodarone Drug Info IC50 = 2.8 nM/mL [34]
Dofetilide Drug Info IC50 = 0.32 nM/mL [36]
Propafenone Drug Info IC50 = 13 nM/mL [35]
Drug Info IC50 = 10000 nM [15]
(1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX) Drug Info IC50 = 7000 nM [21]
(2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 120 nM [30]
(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine Drug Info Ki = 3900 nM [10]
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine Drug Info Ki = 16400 nM [19]
(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline Drug Info Ki = 10000 nM [27]
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide Drug Info Ki = 7000 nM [25]
(R)-ONDANSETRON Drug Info IC50 = 810 nM [11]
(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine Drug Info Ki = 15700 nM [19]
1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane Drug Info Ki = 300 nM [29]
1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane Drug Info Ki = 2400 nM [29]
1,6-bis(4-m-tolylpiperazin-1-yl)hexane Drug Info Ki = 2200 nM [29]
1,6-bis(4-phenylpiperazin-1-yl)hexane Drug Info Ki = 8000 nM [29]
1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Drug Info IC50 = 760 nM [28]
1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) Drug Info IC50 = 4950 nM [28]
1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine Drug Info IC50 = 5840 nM [28]
1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) Drug Info IC50 = 15300 nM [28]
1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine Drug Info Ki = 8500 nM [19]
2-Phenyl-3-piperidin-3-yl-1H-indole Drug Info Ki = 4900 nM [1]
2-Phenyl-3-piperidin-4-yl-1H-indole Drug Info Ki = 5700 nM [1]
2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole Drug Info IC50 = 2000 nM [13]
3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole Drug Info Ki = 290 nM [1]
3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole Drug Info Ki = 7000 nM [1]
3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole Drug Info Ki = 9600 nM [1]
3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole Drug Info Ki = 530 nM [1]
3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole Drug Info Ki = 80 nM [1]
3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine Drug Info IC50 = 1000 nM [15]
3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine Drug Info IC50 = 11000 nM [15]
4-((naphthalen-2-yloxy)methyl)piperidine Drug Info Ki = 3800 nM [19]
4-(2-thienyl)benzene-1,2-diamine Drug Info IC50 = 1600 nM [17]
4-(3-thienyl)benzene-1,2-diamine) Drug Info IC50 = 1500 nM [17]
4-(p-Tolyl)spiro[chromene-2,4'-piperidine] Drug Info IC50 = 462 nM [14]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Drug Info IC50 = 11589 nM [24]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol Drug Info IC50 = 643 nM [14]
4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine Drug Info Ki = 2500 nM [2]
4-Benzenesulfonyl-1-phenethyl-piperidine Drug Info Ki = 1800 nM [2]
4-Phenylspiro[chromene-2,4'-piperidine] Drug Info IC50 = 680 nM [14]
5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole Drug Info IC50 = 9000 nM [15]
5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole Drug Info IC50 = 7000 nM [15]
5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix) Drug Info IC50 = 9000 nM [15]
5-(3-butylpyrrolidin-3-yl)-1H-indole Drug Info IC50 = 4400 nM [15]
5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole Drug Info IC50 = 3500 nM [3]
6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 40 nM [30]
7-(piperidin-4-ylmethoxy)-2-naphthonitrile Drug Info Ki = 3500 nM [19]
8-azabicyclo[3.2.1]octan-3-yloxy-benzamide Drug Info IC50 = 260 nM [33]
ADS-103253 Drug Info IC50 = 10000 nM [8]
AZD-5438 Drug Info IC50 = 3200 nM [16]
BETRIXABAN Drug Info IC50 = 8900 nM [32]
BMS-645737 Drug Info IC50 = 6600 nM [12]
Brivanib Drug Info IC50 = 18000 nM [6]
Desmethylastemizole Drug Info IC50 = 9000 nM [4]
DESMETHYLOLANZAPINE Drug Info IC50 = 14200 nM [21]
E-4031 Drug Info IC50 = 10.2 nM [5]
GW803430 Drug Info IC50 = 1170 nM [20]
ISOQUINE Drug Info IC50 = 7500 nM [18]
ISOQUINE Drug Info IC50 = 3900 nM [18]
JNJ-10392980 Drug Info IC50 = 1000 nM [13]
M100907 Drug Info Ki = 1100 nM [31]
MDL-74156 Drug Info IC50 = 5230 nM [4]
MK-1925 Drug Info IC50 = 9500 nM [22]
MK-499 Drug Info IC50 = 34 nM [3]
N-(4-(benzyloxy)phenethyl)pyridin-4-amine Drug Info IC50 = 130 nM [9]
N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) Drug Info IC50 = 380 nM [30]
N-(piperidin-4-yl)-N-propyl-2-naphthamide Drug Info Ki = 12700 nM [25]
N-DESMETHYLCLOZAPINE Drug Info IC50 = 4490 nM [21]
N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) Drug Info IC50 = 2470 nM [26]
PF-526014 Drug Info IC50 = 6950 nM [28]
PRUVANSERIN Drug Info Ki = 1268 nM [7]
R-dimethindene Drug Info IC50 = 900 nM [23]
TERIKALANT Drug Info IC50 = 6600 nM [4]
TERIKALANT Drug Info IC50 = 6700 nM [4]
VESNARINONE Drug Info IC50 = 5960 nM [4]
References
REF 1 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14.
REF 2 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem. 2002 Jan 17;45(2):492-503.
REF 3 Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett. 2003 May 19;13(10):1829-35.
REF 4 Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
REF 5 Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor an... J Med Chem. 2004 Apr 22;47(9):2318-25.
REF 6 Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-... J Med Chem. 2006 Apr 6;49(7):2143-6.
REF 7 A new class of selective, non-basic 5-HT2A receptor antagonists. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3201-4.
REF 8 Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
REF 9 Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetr... J Med Chem. 2007 Feb 22;50(4):807-19.
REF 10 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8.
REF 11 A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem. 2008 Apr 1;16(7):4107-19.
REF 12 Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]t... Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9.
REF 13 Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
REF 14 Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
REF 15 Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6.
REF 16 Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9.
REF 17 Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1168-72.
REF 18 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
REF 19 Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
REF 20 Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concen... J Med Chem. 2009 Apr 9;52(7):2076-89.
REF 21 Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new ... J Med Chem. 2009 Jul 23;52(14):4266-76.
REF 22 Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32.
REF 23 Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10.
REF 24 Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
REF 25 Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
REF 26 Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37.
REF 27 In vitro studies on a class of quinoline containing histamine H3 antagonists. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300.
REF 28 Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
REF 29 Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7.
REF 30 Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4.
REF 31 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
REF 32 Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem. 2010 Sep 9;53(17):6243-74.
REF 33 SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
REF 34 Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation. 2001 Mar 6;103(9):1317-24.
REF 35 Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):472-80.
REF 36 Molecular determinants of dofetilide block of HERG K+ channels. Circ Res. 1998 Feb 23;82(3):386-95.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.